These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 28255099)

  • 1. N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation.
    Svennberg E; Henriksson P; Engdahl J; Hijazi Z; Al-Khalili F; Friberg L; Frykman V
    Heart; 2017 Aug; 103(16):1271-1277. PubMed ID: 28255099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and echocardiographic characteristics of individuals aged 75/76 years old with screening-detected elevated NT-proBNP levels.
    Al-Khalili F; Kemp-Gudmundsdottir K; Svennberg E; Fredriksson T; Frykman V; Friberg L; Rosenqvist M; Engdahl J
    Open Heart; 2020; 7(1):e001200. PubMed ID: 32153793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design.
    Engdahl J; Svennberg E; Friberg L; Al-Khalili F; Frykman V; Kemp Gudmundsdottir K; Fredriksson T; Rosenqvist M
    Europace; 2017 Feb; 19(2):297-302. PubMed ID: 28011798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of N-terminal pro-B-type natriuretic peptide level in screening for atrial fibrillation in primary health care.
    Ghazal F; Theobald H; Rosenqvist M; Al-Khalili F
    PLoS One; 2019; 14(2):e0212974. PubMed ID: 30807614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study.
    Xiao J; Persson AP; Engström G; Johnson LSB
    BMC Cardiovasc Disord; 2021 Mar; 21(1):134. PubMed ID: 33711943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
    Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
    Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
    Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated admission N-terminal pro-brain natriuretic peptide level predicts the development of atrial fibrillation in general surgical intensive care unit patients.
    Chokengarmwong N; Yeh DD; Chang Y; Ortiz LA; Kaafarani HMA; Fagenholz P; King DR; DeMoya M; Butler K; Lee J; Velmahos G; Januzzi JL; Lee-Lewandrowski E; Lewandrowski K
    J Trauma Acute Care Surg; 2017 Sep; 83(3):485-490. PubMed ID: 28463935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NT-proBNP is a powerful predictor for incident atrial fibrillation - Validation of a multimarker approach.
    Svennberg E; Lindahl B; Berglund L; Eggers KM; Venge P; Zethelius B; Rosenqvist M; Lind L; Hijazi Z
    Int J Cardiol; 2016 Nov; 223():74-81. PubMed ID: 27541645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
    J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure].
    Pokorná V; Jurkovicová O; Kaluzay J; Stecová A; Pont'uch P
    Vnitr Lek; 2010 Aug; 56(8):788-94. PubMed ID: 20845610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of N-terminal pro B-type natriuretic peptide (NT-proBNP) change with the risk of atrial fibrillation in the ARIC cohort.
    Li L; Selvin E; Lutsey PL; Hoogeveen RC; O'Neal WT; Soliman EZ; Chen LY; Alonso A
    Am Heart J; 2018 Oct; 204():119-127. PubMed ID: 30099337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study.
    Xing LY; Diederichsen SZ; Højberg S; Krieger DW; Graff C; Frikke-Schmidt R; Olesen MS; Brandes A; Køber L; Haugan KJ; Svendsen JH
    Circulation; 2023 Jun; 147(24):1788-1797. PubMed ID: 37061802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint Associations of Obesity and NT-proBNP With the Incidence of Atrial Fibrillation in the ARIC Study.
    Almuwaqqat Z; O'Neal WT; Norby FL; Lutsey PL; Selvin E; Soliman EZ; Chen LY; Alonso A
    J Am Heart Assoc; 2019 Oct; 8(19):e013294. PubMed ID: 31564186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation.
    Staszewsky L; Meessen JMTA; Novelli D; Wienhues-Thelen UH; Disertori M; Maggioni AP; Masson S; Tognoni G; Franzosi MG; Lucci D; Latini R
    BMC Cardiovasc Disord; 2021 Nov; 21(1):553. PubMed ID: 34798808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
    Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
    Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of NT-proANP and NT-proBNP in patients with atrial fibrillation: Association with atrial fibrillation progression phenotypes.
    Büttner P; Schumacher K; Dinov B; Zeynalova S; Sommer P; Bollmann A; Husser D; Hindricks G; Kornej J
    Heart Rhythm; 2018 Aug; 15(8):1132-1137. PubMed ID: 29604419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.
    Shelton RJ; Clark AL; Goode K; Rigby AS; Cleland JG
    Eur Heart J; 2006 Oct; 27(19):2353-61. PubMed ID: 16952921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of atrial fibrillation burden and N-terminal pro-brain natriuretic peptide.
    Plitt DC; Chung EH; Mounsey JP; Schwartz JD; Pursell IW; Gehi AK
    Am J Cardiol; 2013 May; 111(9):1315-8. PubMed ID: 23415637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study.
    Kemp Gudmundsdottir K; Fredriksson T; Svennberg E; Al-Khalili F; Friberg L; Frykman V; Hijazi Z; Rosenqvist M; Engdahl J
    Europace; 2020 Jan; 22(1):24-32. PubMed ID: 31790147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.